Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon
about
Interferon-inducible antiviral effectorsCurrent status of novel antifibrotic therapies in patients with chronic liver disease2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine.The personal touch: strategies toward personalized vaccines and predicting immune responses to them.Tumour necrosis factor -308 and -238 promoter polymorphisms are predictors of a null virological response in the treatment of Brazilian hepatitis C patients.Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan.Host genetic variations are associated with virological response to interferon therapy of chronic HCV in Han Chinese patients.Pharmacogenomics of drug efficacy in the interferon treatment of chronic hepatitis C using classification algorithms.Genetics of liver disease: immunogenetics and disease pathogenesis.Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection.Host genetic determinants in hepatitis C virus infection.Activation of type I interferon-dependent genes characterizes the "core response" induced by CpG DNA.IL28B polymorphism and cytomegalovirus predict response to treatment in Egyptian HCV type 4 patientsLearning from the messengers: innate sensing of viruses and cytokine regulation of immunity - clues for treatments and vaccines.Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies.The myxovirus resistance A (MxA) gene -88G>T single nucleotide polymorphism is associated with prostate cancer.Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trialRole of viral and host factors in interferon based therapy of hepatitis C virus infectionMolecular cloning, polymorphism, and functional activity of the bovine and water buffalo Mx2 gene promoter regionMx1, OAS1 and OAS2 polymorphisms are associated with the severity of liver disease in HIV/HCV-coinfected patients: A cross-sectional study.Genetic polymorphisms in host antiviral genes: associations with humoral and cellular immunity to measles vaccine.Assessing gene-gene interactions in pharmacogenomics.The interferon signaling pathway genes as biomarkers of hepatitis C virus disease progression and response to treatment.Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy.Functional characterization of new allelic polymorphisms identified in the promoter region of the human MxA gene.Gene polymorphisms of IL-10 and MxA in responders and non-responders to interferon therapy in HCV Egyptian patients genotype 4.An artificial neural network approach to the drug efficacy of interferon treatments.Myxovirus resistance 1 gene polymorphisms and outcomes of viral hepatitis B and C infections in Moroccan patients.Association of functional polymorphisms in the MxA gene with susceptibility to enterovirus 71 infection.Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese.Innate immunity: a new chapter for hepatitis C.A support vector machine approach to assess drug efficacy of interferon-alpha and ribavirin combination therapy.Single nucleotide polymorphisms and haplotypes in the IL10 region associated with HCV clearance.Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR.Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy.MxA transcripts with distinct first exons and modulation of gene expression levels by single-nucleotide polymorphisms in human bronchial epithelial cells.Strategies for genotyping.
P2860
Q27486790-698C6998-6CB3-4CFC-8AA2-ED9B93B13ED0Q30473375-F538823E-EB06-4529-A0CF-6BEE295C6FF3Q33742272-2BFA0285-C427-40F9-9782-310C412634D8Q33813977-D39AB5E6-F8F4-4C05-9DE2-260020A9CBB2Q34040606-19111DFD-9EF8-4780-ADFA-49A6E5D0D328Q34484305-83C6461A-4851-4390-A16F-7E9E76D14AF8Q34604371-D38B26C7-6D2B-4131-874B-46F2636590C2Q35205520-E3C91D29-3D87-4034-A492-F9760E41937FQ35596380-F25BC1A7-CA94-4FD0-B507-249895C5AA67Q35740155-49D51CE8-B8A9-45DC-ACB2-9DAE10FEEF5BQ35753723-A71FC161-7101-4B1D-9B38-9F58D3435019Q36232223-0A79F46E-9B84-4A65-9A7A-92F681427A3BQ36541206-31B4A382-C7F7-45FE-AFFC-9F03A01BC87EQ36807121-768CC5CC-8D88-4598-863B-CE6AFF6011EAQ36890411-CFC3C533-AE39-4470-B5A5-131A66F1E11DQ36892193-E27550E9-0B12-46F7-AAE2-19210542E11CQ37028594-82A37C50-3C01-49B6-8BF6-0458868E66D1Q37217280-601C2672-A942-470A-B2C0-9FEC6D260A1AQ37362240-635F3E77-E07A-4461-BB7C-987F348FA376Q37528418-5065C165-72B5-4BB9-9448-67D40469FD43Q37615221-1456632A-BBCD-406C-8BBF-3D7DA364DCA6Q37616442-07FCA20C-630A-4BEE-B065-70B2B8A52FEFQ37986775-6036BBD3-50A8-4E09-916C-37ED9DD397C9Q37997042-01C4A01E-517E-4CF3-A466-BB69726095F0Q38984116-14EBBB85-65D3-4C0E-9990-760F320C9D2CQ39277224-DEF288BC-9EFB-40B0-8F6D-70DE3E32A685Q39450473-318AB59F-71B2-44F6-9CF2-4B803F9B3348Q40277321-B8E1C8E6-5BE9-4C38-A837-7D0AF6927143Q40599607-1255B9A8-C227-4DB1-A184-B44C51CB5E3DQ42265407-C950D416-30DF-4E37-8DB7-5B7AAE7C8AEAQ42278785-163CA9DD-7FAD-43E9-A7B2-82A9529B7F25Q42406719-CE5DB2FC-D49A-42D5-B1A6-35D26BD4EA61Q42980284-0F55B144-539D-4D2F-9B5A-F12D4CD30B7FQ42991714-4FAC8B48-AD27-4CD2-8664-DF02B0CB1026Q43036174-33578BC1-856D-4F97-A3C7-4FCB5224ED12Q43037177-33E90370-B9B5-425F-B162-C0203D236CF8Q43046800-F274C618-1DC6-4655-8931-D83344C2ECE8Q43048075-7F58FCF8-6340-464A-BB9B-1A044EA5B8D3Q43836592-73B4BE3A-A177-4A11-9666-20776FC04CBFQ44128404-301C03F0-6754-4E74-BD44-A528674E9A41
P2860
Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon
description
2000 nî lūn-bûn
@nan
2000 թուականին հրատարակուած գիտական յօդուած
@hyw
2000 թվականին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Identification of a single nuc ...... titis C patients to interferon
@ast
Identification of a single nuc ...... titis C patients to interferon
@en
Identification of a single nuc ...... titis C patients to interferon
@nl
type
label
Identification of a single nuc ...... titis C patients to interferon
@ast
Identification of a single nuc ...... titis C patients to interferon
@en
Identification of a single nuc ...... titis C patients to interferon
@nl
prefLabel
Identification of a single nuc ...... titis C patients to interferon
@ast
Identification of a single nuc ...... titis C patients to interferon
@en
Identification of a single nuc ...... titis C patients to interferon
@nl
P356
P1433
P1476
Identification of a single nuc ...... titis C patients to interferon
@en
P2093
P356
10.1159/000025035
P407
P577
2000-01-01T00:00:00Z